Form 8-K - Current report:
SEC Accession No. 0001628280-25-012335
Filing Date
2025-03-12
Accepted
2025-03-12 16:02:50
Documents
19
Period of Report
2025-03-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mlys-20250311.htm   iXBRL 8-K 35291
2 EX-1.1 exhibit11-closing8xk.htm EX-1.1 265233
3 EX-5.1 exhibit51-closing8xk.htm EX-5.1 21113
4 EX-99.1 exhibit991-closing8xk.htm EX-99.1 9904
5 EX-99.2 exhibit992-closing8xk.htm EX-99.2 10084
9 lwlogoa.jpg GRAPHIC 104169
10 mineralyslogoa.jpg GRAPHIC 9896
  Complete submission text file 0001628280-25-012335.txt   701365

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mlys-20250311.xsd EX-101.SCH 1794
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mlys-20250311_lab.xml EX-101.LAB 23449
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mlys-20250311_pre.xml EX-101.PRE 13589
21 EXTRACTED XBRL INSTANCE DOCUMENT mlys-20250311_htm.xml XML 2928
Mailing Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087
Business Address 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087 (888) 378-6240
Mineralys Therapeutics, Inc. (Filer) CIK: 0001933414 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41614 | Film No.: 25731664
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)